Reimbursement Review Reports


( Last Updated : May 25, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Xeljanz tofacitinib Cancelled
TBC filgrastim Cancelled
Admelog Insulin lispro Cancelled
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete
Inspiolto Respimat Tiotropium / olodaterol List with criteria/condition Complete
Translarna ataluren Cancelled
Viibryd vilazodone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Imbruvica ibrutinib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Revolade eltrombopag CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Symdeko tezacaftor/ivacaftor CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed